Melanotan I vs Gonadorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | Gonadorelin |
|---|---|---|
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. |
| Best For |